Showing results (2011-2020 of 2,107) with videos related to
Sort By:
Pageof 211
CNS Drugs|April 16, 2021
Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study ReportEmma Morton, Venkat Bhat, Peter Giacobbe, et al.CNS Drugs|April 15, 2021
Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit/Hyperactivity Disorder: A Claims Database Analysis Across the USASepehr Farahbakhshian, Rajeev Ayyagari, Daniel S Barczak, et al.CNS Drugs|April 18, 2021
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 TherapiesMilo Gatti, Fabrizio De Ponti, Federico PeaCNS Drugs|April 13, 2021
Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect ComparisonStanley Cohan, Jinender Kumar, Stella Arndorfer, et al.CNS Drugs|April 11, 2021
Pharmacotherapy for Frontotemporal DementiaRita Khoury, Yu Liu, Quratulanne Sheheryar, et al.CNS Drugs|March 20, 2010
Defining and measuring functional recovery from depressionTracy L Greer, Benji T Kurian, Madhukar H TrivediCNS Drugs|March 20, 2010
Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literatureSalma R I Ribeiz, Débora P Bassitt, Jony A Arrais, et al.CNS Drugs|March 20, 2010
OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe painNatalie J Carter, Gillian M KeatingCNS Drugs|June 5, 2014
Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in DenmarkBjörn Pasternak, Henrik Svanström, Mattis F Ranthe, et al.CNS Drugs|September 29, 2012
Drug interactions with triptans : which are clinically significant?Paul E RolanPageof 211